These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 29962245)

  • 1. Comparative functional and pharmacological characterization of Sandoz proposed biosimilar adalimumab (GP2017): rationale for extrapolation across indications.
    Kronthaler U; Fritsch C; Hainzl O; Seidl A; da Silva A
    Expert Opin Biol Ther; 2018 Aug; 18(8):921-930. PubMed ID: 29962245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GP2017: An Adalimumab Biosimilar.
    Heo YA
    BioDrugs; 2018 Dec; 32(6):635-638. PubMed ID: 30460599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods.
    von Richter O; Lemke L; Haliduola H; Fuhr R; Koernicke T; Schuck E; Velinova M; Skerjanec A; Poetzl J; Jauch-Lembach J
    Expert Opin Biol Ther; 2019 Oct; 19(10):1075-1083. PubMed ID: 30698045
    [No Abstract]   [Full Text] [Related]  

  • 4. Demonstration of functional similarity of a biosimilar adalimumab SB5 to Humira
    Lee JJ; Yang J; Lee C; Moon Y; Ahn S; Yang J
    Biologicals; 2019 Mar; 58():7-15. PubMed ID: 30744947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel(®)).
    Hofmann HP; Kronthaler U; Fritsch C; Grau R; Müller SO; Mayer R; Seidl A; Da Silva A
    Expert Opin Biol Ther; 2016 Oct; 16(10):1185-95. PubMed ID: 27463856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches.
    Blauvelt A; Lacour JP; Fowler JF; Weinberg JM; Gospodinov D; Schuck E; Jauch-Lembach J; Balfour A; Leonardi CL
    Br J Dermatol; 2018 Sep; 179(3):623-631. PubMed ID: 29917226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'Totality of Evidence' Approach in the Development of GP2017, an Approved Adalimumab Biosimilar.
    Gaylis N; Both C; Lemke L; von Richter O; Yamauchi P
    Adv Ther; 2024 May; 41(5):1795-1814. PubMed ID: 38514505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Update Review of Biosimilars of Adalimumab in Psoriasis - Bioequivalence and Interchangeability.
    Zhou X; Chen Z; Bi X
    Drug Des Devel Ther; 2021; 15():2987-2998. PubMed ID: 34267501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FKB327: An Adalimumab Biosimilar.
    Al-Salama ZT
    BioDrugs; 2019 Feb; 33(1):113-116. PubMed ID: 30712241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab.
    Velayudhan J; Chen YF; Rohrbach A; Pastula C; Maher G; Thomas H; Brown R; Born TL
    BioDrugs; 2016 Aug; 30(4):339-51. PubMed ID: 27422671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PF-06410293: An Adalimumab Biosimilar.
    Lee A; Shirley M
    BioDrugs; 2020 Oct; 34(5):695-698. PubMed ID: 32949384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501.
    Markus R; McBride HJ; Ramchandani M; Chow V; Liu J; Mytych D; Fanjiang G
    Adv Ther; 2019 Aug; 36(8):1833-1850. PubMed ID: 31183781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative nonclinical assessments of the biosimilar PF-06410293 and originator adalimumab.
    Derzi M; Shoieb AM; Ripp SL; Finch GL; Lorello LG; O'Neil SP; Radi Z; Syed J; Thompson MS; Leach MW
    Regul Toxicol Pharmacol; 2020 Apr; 112():104587. PubMed ID: 32006671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABP 501 for the treatment of rheumatoid arthritis.
    Pelechas E; Voulgari PV; Drosos AA
    Expert Opin Biol Ther; 2018 Mar; 18(3):317-322. PubMed ID: 29350566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioequivalence of Biosimilar Tumor Necrosis Factor-α Inhibitors Compared With Their Reference Biologics: A Systematic Review.
    Chingcuanco F; Segal JB; Kim SC; Alexander GC
    Ann Intern Med; 2016 Oct; 165(8):565-574. PubMed ID: 27479870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab.
    Schreiber S; Yamamoto K; Muniz R; Iwura T
    Pharmacol Res Perspect; 2020 Jun; 8(3):e00604. PubMed ID: 32500668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SB5: An Adalimumab Biosimilar.
    Frampton JE
    BioDrugs; 2018 Oct; 32(5):507-510. PubMed ID: 30251234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The First WHO International Standard for Adalimumab: Dual Role in Bioactivity and Therapeutic Drug Monitoring.
    Wadhwa M; Bird C; Atkinson E; Cludts I; Rigsby P
    Front Immunol; 2021; 12():636420. PubMed ID: 33936049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scientific and statistical considerations in evaluating the analytical similarity of ABP 501 to adalimumab.
    Sivendran R; Ramírez J; Ramchandani M; Liu J
    Immunotherapy; 2018 Aug; 10(11):1011-1021. PubMed ID: 30071739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.